|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||52.17 / 109.05|
Veeva Systems (NYSE:VEEV), a provider of quality and regulatory cloud software for the consumer goods, cosmetics, chemical, and life sciences industries, today announced Laboratoires FILL-MED, a Filorga Group company, and Novacap are adopting Veeva...
Veeva Systems: What: Veeva Systems (NYSE:VEEV) will celebrate the grand opening of its major regional office in Columbus, Ohio.
Veeva Systems Inc. (NYSE: VEEV), a leading industry cloud provider for life sciences, will announce financial results for its fiscal third quarter which ended October 31, 2018 after market close on November 28, 2018.
Veeva Systems (NYSE:VEEV) today announced that Menarini, an Italian-based biopharmaceutical company, selected Veeva CRM to improve commercial execution throughout its over-the-counter (OTC) business.
The Goldsmith era at Instructure has started with a bang. He and his predecessor Josh Coates sit down with Real Money's Kevin Curran to discuss his company and the overall tech sector. Watch the video.
The software sector's acquisition boom has some obvious key catalysts.
The momentum of acquisitions isn't stalling. Here's what names might be in the mix.
I can see this group bottoming a heck of a lot faster than others.
Jim Cramer evaluates the Federal Reserve's interest-rate moves and says it's right to stay focused on any form of inflation.
VEEV's price chart that is showing weakness.
Veeva Systems (NYSE:VEEV) today introduced its first application specifically built for clinical research centers, Veeva Vault SiteDocs.
Veeva Systems (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, will host its financial analyst and investor day in New York on Thursday, October 4, 2018.
Addressing Demand for Meaningful Insights to the Field
2018 Veeva R&D Summit -- Veeva Systems (NYSE:VEEV) today announced a next-generation cloud application to streamline clinical data management and accelerate study execution.
Modernizing quality management is becoming a top priority among leading life sciences companies.
Veeva Systems (NYSE:VEEV) today announced increasing numbers of medical devices and diagnostics (MD&D) companies are adopting Veeva Vault applications to streamline content and data management in clinical, quality, and commercial.
Veeva Systems (NYSE: VEEV), a leading industry cloud provider for life sciences, today announced that Tim Cabral, CFO, will present at the Deutsche Bank 2018 Technology Conference on Thursday, September 13, 2018, at 10:00 a.
Veeva Systems (NYSE:VEEV) today announced the availability of Veeva Vault Submissions Publishing, a new cloud application in the Veeva Vault RIM Suite to unify publishing and submission document authoring.
Over the past year, growing numbers of customers are adopting Veeva Vault CTMS to empower clinical teams with one complete source of trial information for faster study execution.
Veeva Systems (NYSE:VEEV) will host the 2018 Veeva R&D Summit from September 16-18 in Philadelphia.
Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its fiscal second quarter ended July 31, 2018.
Veeva Systems Inc. (NYSE: VEEV), a leading industry cloud provider for life sciences, will announce financial results for its fiscal second quarter which ended July 31, 2018 after market close on August 23, 2018.
Veeva Systems (NYSE:VEEV) today announced that more life sciences companies are adopting Veeva OpenData to empower their field teams with faster, accurate customer data.
Veeva Systems (NYSE:VEEV) today announced that Samsung BioLogics selected Veeva Vault QualityDocs to modernize quality document management.
Veeva Systems (NYSE:VEEV) today announced that Idorsia Pharmaceuticals Ltd established an integrated development landscape with Veeva Development Cloud.
Veeva Systems (NYSE:VEEV) today announced that leading pharmaceutical companies and CROs are now using Veeva Vault EDC to improve data management in their clinical trials.
At the upcoming DIA 2018 Annual Meeting, Tufts Center for the Study of Drug Development (CSDD) will preview its study findings on the root causes for delays and inefficiencies impacting trial timelines.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.